 |
1 Disease |  |
67 Trials |
|
67 Trials |  |
1555 News |  |
| «12...28293031323334353637383940 |
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Enrollment change: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 18, 2017
P1, N=398, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting | N=560 --> 398
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Aug 22, 2017
P1, N=24, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=560 --> 398 Active, not recruiting --> Recruiting
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P3 trial: EMPOWER-Cervical 1: Study of Cemiplimab in Adults With Cervical Cancer (clinicaltrials.gov) - Aug 21, 2017
P3, N=436, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial: R2810-ONC-1622: Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 27, 2017
P1, N=6, Recruiting, Sponsor: Regeneron Pharmaceuticals
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Jun 29, 2017
P1, N=24, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Recruiting Suspended --> Active, not recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial suspension: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Jun 27, 2017
P1, N=24, Suspended, Sponsor: Mayo Clinic
Suspended --> Active, not recruiting Recruiting --> Suspended
- Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Enrollment open, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Jun 26, 2017
P1, N=30, Recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: R2810-ONC-1620: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy (clinicaltrials.gov) - Jun 26, 2017
P2, N=137, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, New P1 trial, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Jun 22, 2017
P1, N=30, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- ||||| Sarclisa (isatuximab-irfc) / Sanofi
New P1/2 trial: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Jun 20, 2017
P1/2, N=54, Not yet recruiting, Sponsor: Sanofi
- ||| SAR439459 / Sanofi
New P1 trial, Monotherapy: A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 20, 2017
P1, N=130, Recruiting, Sponsor: Sanofi
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, Trial initiation date: EMPOWER-lung 1: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 7, 2017
P3, N=300, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> May 2017
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: R2810-ONC-1620: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy (clinicaltrials.gov) - Apr 27, 2017
P2, N=137, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Enrollment open, Trial initiation date, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Apr 14, 2017
P1, N=30, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> May 2017 Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Apr 2017
- || Libtayo (cemiplimab-rwlc) / Regeneron, Ordspono (odronextamab) / Regeneron
Enrollment change: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - Apr 13, 2017
P1, N=154, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Apr 2017 N=318 --> 154
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Apr 11, 2017
P1, N=24, Recruiting, Sponsor: Mayo Clinic
N=318 --> 154 Not yet recruiting --> Recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, Trial primary completion date: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Mar 23, 2017
P1, N=24, Not yet recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Initiation date: Jan 2017 --> Jun 2017 | Trial primary completion date: Jan 2017 --> Jan 2021
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P3 trial: EMPOWER-lung 1: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 23, 2017
P3, N=300, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Jan 11, 2017
P1, N=24, Not yet recruiting, Sponsor: Mayo Clinic
- | Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, New P1 trial, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Dec 22, 2016
P1, N=30, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial primary completion date: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 21, 2016
P1, N=560, Recruiting, Sponsor: Regeneron Pharmaceuticals
Initiation date: Jan 2017 --> Jun 2017 | Trial primary completion date: Jan 2017 --> Jan 2021 N=973 --> 560 | Trial primary completion date: Dec 2018 --> Jul 2019
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=973 --> 560 | Trial primary completion date: Dec 2018 --> Jul 2019 Trial primary completion date: May 2018 --> Dec 2018
- || Libtayo (cemiplimab-rwlc) / Regeneron, Ordspono (odronextamab) / Regeneron
Enrollment change: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - Nov 18, 2016
P1, N=318, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: May 2018 --> Dec 2018 N=154 --> 318
- Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial withdrawal: Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study (clinicaltrials.gov) - Nov 7, 2016
P1, N=0, Withdrawn, Sponsor: Regeneron Pharmaceuticals
N=154 --> 318 N=60 --> 0 | Enrolling by invitation --> Withdrawn
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=60 --> 0 | Enrolling by invitation --> Withdrawn N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study (clinicaltrials.gov) - May 18, 2016
P1, N=60, Enrolling by invitation, Sponsor: Regeneron Pharmaceuticals
N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018 Not yet recruiting --> Enrolling by invitation
- || Libtayo (cemiplimab-rwlc) / Regeneron, Ordspono (odronextamab) / Regeneron
Enrollment change: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - May 3, 2016
P1, N=154, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Enrolling by invitation N=72 --> 154
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: EMPOWER-CSCC-1 : Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - May 3, 2016
P2, N=129, Recruiting, Sponsor: Regeneron Pharmaceuticals
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 11, 2016
P1, N=973, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=72 --> 154 N=60 --> 973
- ||| Libtayo (cemiplimab-rwlc) / Regeneron, Ordspono (odronextamab) / Regeneron
New P1 trial: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - Jan 11, 2016
P1, N=72, Recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial: Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study (clinicaltrials.gov) - Aug 11, 2015
P1, N=60, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=1200, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=60 --> 973 N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017
- ||||| Hiltonol (poly-ICLC) / Oncovir
New P2 trial: In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol (clinicaltrials.gov) - Apr 22, 2015
P2, N=100, Recruiting, Sponsor: Oncovir, Inc.
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 9, 2015
P1, N=60, Recruiting, Sponsor: Regeneron Pharmaceuticals
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P2, N=800, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017 Trial primary completion date: Feb 2014 --> Sep 2015